Evidence map›Paper›PMID 42007169›Full record

ArticleExploratory research in clinical and social pharmacy2026

The role of community pharmacies in the provision of human papillomavirus (HPV) self-testing: A range of delivery models and proof-of-concept study.

Karen Bartholomew, Lily P H Yang, Cleo Neville, Anna Maxwell, Joanna Hikaka, Jane Grant, Collette Bromhead, Georgina McPherson, Kate Moodabe, Richard Massey and 7 more

Abstract read
In one paragraph

Article in Exploratory research in clinical and social pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Karen BartholomewHealth Gain Development, Planning, Funding and Outcomes, Health New Zealand | Te Whatu Ora, Auckland, New Zealand.
Lily P H YangHealth Gain Development, Planning, Funding and Outcomes, Health New Zealand | Te Whatu Ora, Auckland, New Zealand.
Cleo NevilleHealth Gain Development, Planning, Funding and Outcomes, Health New Zealand | Te Whatu Ora, Auckland, New Zealand.
Anna MaxwellHealth Gain Development, Planning, Funding and Outcomes, Health New Zealand | Te Whatu Ora, Auckland, New Zealand.
Joanna HikakaTe Kupenga Hauora Māori University of Auckland, Auckland, New Zealand.
Jane GrantChild, Youth and Women, Planning, Funding and Outcomes, Health New Zealand | Te Whatu Ora, Auckland, New Zealand.
Collette BromheadMolecular Pathology, School of Health Sciences, Massey University, Palmerston North, New Zealand.
Georgina McPhersonWomen's Health, Waitematā District, Health New Zealand | Te Whatu Ora, Auckland, New Zealand.
Kate MoodabeTotal Healthcare, Auckland, New Zealand.
Richard MasseyPathology Associates New Zealand, Tauranga, New Zealand.
Sue CrengleNgāi Tahi Māori Health Research Unit, University of Otago, Dunedin, New Zealand.
Susan M ShermanSchool of Psychology, University of Sheffield, Sheffield, England, UK.
Nina ScottHauora Māori Services, Health New Zealand | Te Whatu Ora, Waikato, New Zealand.
Pania CooteMāori Monitoring Equity Group (National Screening Programmes), AwhiMai Consultancy, Bluff, New Zealand.
Wendy BurgessWomen's Health, Waitematā District, Health New Zealand | Te Whatu Ora, Auckland, New Zealand.
Deralie FlowerObstetrics and Gynaecology, Te Toka Tumai Auckland District, Health New Zealand | Te Whatu Ora, Auckland, New Zealand.
Jyoti KathuriaWomen's Health, Counties Manukau District, Health New Zealand | Te Whatu Ora, Auckland, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cervical cancer persists in Aotearoa New Zealand, mainly due to under-screening. Longstanding disparities in screening and cancer rates remain for Māori, Pacific and people not regularly screened. Community pharmacies are an important and accessible part of primary care. Objective: To outline and provide potential models of pharmacy involvement in the provision of HPV self-testing. Of the three potential models proposed, our proof-of-concept study trialled two models: 1) promotion of human papillomavirus (HPV) self-testing by pharmacy staff, with mailed test kits from the centralised co-ordination team, and 2) on-site provision of at-home self-test kits by study nurses, both with telehealth support and results follow-up from the study team to expand self-test access. Methods: Six Auckland community pharmacies with high proportions of female Māori and Pacific customers (based on dispensing data) participated in the study for 6 weeks from May to July 2024. All pharmacies participated in the promotion model and one participated in the on-site provision model. Results: Although our numbers were small ( Conclusions: Community pharmacies, supported by a centralised co-ordination team, appropriate infrastructure and resources, may be an additional setting for further research to increase access to HPV self-testing for Māori, Pacific, under-screened people, and those not enrolled with a primary care provider.

Indexed as

Aotearoa New ZealandAt-home testingCervical screeningCommunity pharmacyHealth inequityHuman papillomavirus (HPV)Māori healthPacific healthPrimary careSelf-sampling

Identifiers

PMID42007169
PMCPMC13089177

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.